Screening for gestational diabetes; past, present and future.

Area of Science:

• Obstetrics and Gynecology
• Endocrinology
• Public Health

Background:

• Gestational diabetes mellitus (GDM) is defined as carbohydrate intolerance with hyperglycemia first recognized during pregnancy.
• Elevated blood glucose levels in pregnancy are linked to adverse maternal and fetal outcomes, supporting screening.
• Concerns exist regarding screening's potential to influence clinical judgment and lead to interventions like cesarean sections, alongside debates on definitive glycaemic thresholds and intervention impacts.

Purpose of the Study:

• To critically evaluate existing data on screening methodologies for gestational diabetes.
• To assess the efficacy and limitations of various diagnostic tests for GDM.
• To review the evidence supporting or refuting the necessity and impact of GDM screening.

Main Methods:

• Systematic review of literature on gestational diabetes screening tests.
• Analysis of diagnostic accuracy (sensitivity/specificity) of different glucose challenge tests.
• Comparison of the Oral Glucose Tolerance Test (OGTT) with alternative screening methods like fasting and random glucose tests.

Main Results:

• The Oral Glucose Tolerance Test (OGTT), particularly the 2-hour/75-g and 3-hour/100-g variations, is considered the most acceptable diagnostic standard despite practical limitations.
• Alternative methods like random glucose testing show poor sensitivity, while fasting glucose tests show promise but require further validation across diverse populations.
• Current screening tests face challenges related to cost, time, patient tolerance of glucose loads, and reproducibility.

Conclusions:

• The OGTT remains the established diagnostic benchmark for gestational diabetes, though its limitations necessitate exploration of more convenient alternatives.
• Further research and validation are crucial for alternative screening methods (fasting, random, post-load glucose) to achieve widespread acceptance.
• Establishing clear glycaemic thresholds and understanding the impact of interventions are critical for refining GDM screening strategies.